Sumitomo Mitsui Trust Group Inc. Raises Holdings in Johnson & Johnson $JNJ

Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,179,488 shares of the company’s stock after purchasing an additional 21,819 shares during the quarter. Johnson & Johnson comprises about 0.7% of Sumitomo Mitsui Trust Group Inc.’s investment portfolio, making the stock its 21st biggest position. Sumitomo Mitsui Trust Group Inc. owned about 0.26% of Johnson & Johnson worth $1,145,801,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. United Bank grew its holdings in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Triumph Capital Management increased its position in shares of Johnson & Johnson by 27.2% in the 2nd quarter. Triumph Capital Management now owns 3,260 shares of the company’s stock worth $498,000 after purchasing an additional 697 shares during the last quarter. First Bank & Trust raised its stake in shares of Johnson & Johnson by 24.5% in the 2nd quarter. First Bank & Trust now owns 12,977 shares of the company’s stock valued at $1,982,000 after purchasing an additional 2,556 shares in the last quarter. Finally, Krilogy Financial LLC lifted its stake in Johnson & Johnson by 20.4% during the second quarter. Krilogy Financial LLC now owns 14,314 shares of the company’s stock worth $2,186,000 after purchasing an additional 2,421 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on JNJ. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Morgan Stanley raised their target price on Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 3 MajesTEC-9 topline: TECVAYLI (teclistamab) monotherapy showed a 71% reduction in risk of progression or death and a 40% reduction in risk of death versus standard of care in early-relapse, largely anti‑CD38/lenalidomide‑refractory myeloma — a potentially significant new earlier-line oncology opportunity that can drive revenue and R&D upside. TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
• Positive Sentiment: Delaware court orders recalculation of damages in Auris/robotics case — the state’s top court overturned part of a ~$1B award and ordered a recalculation that could materially reduce J&J’s payout exposure, lowering legal risk on the balance sheet. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Positive Sentiment: MedTech momentum: Zacks highlights growth driven by cardiovascular strength and new product rollouts, supporting the MedTech segment’s contribution even as China weakness lingers — a constructive signal for recurring revenue. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: Psychiatry pipeline/data: New CAPLYTA and SPRAVATO analyses being presented at ACNP reinforce J&J’s CNS franchise and could support future label or adoption upside. Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
• Neutral Sentiment: Company expected to report quarterly results this week — keep an eye on guidance, MedTech trends and margins; earnings timing may create short-term volatility but is routine. Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Wednesday
• Neutral Sentiment: Investor attention spikes: Zacks notes heavy search/interest in JNJ — increased attention can amplify moves around data and earnings. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
• Neutral Sentiment: Dividend visibility: JNJ features in dividend-focused lists (Dogs of the Dow coverage); this underpins income investor interest but is unlikely to move shares materially on its own. The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%
• Negative Sentiment: Zacks preview flags J&J may lack the setup for an earnings beat next week — if results or guidance disappoint, that could reverse some of today’s gains. Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth

Johnson & Johnson Price Performance

JNJ opened at $218.53 on Thursday. The firm has a market capitalization of $526.51 billion, a P/E ratio of 21.09, a PEG ratio of 2.19 and a beta of 0.34. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $218.86. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a fifty day moving average of $204.52 and a 200-day moving average of $186.04.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.76 by $0.04. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $23.99 billion during the quarter, compared to analysts’ expectations of $23.73 billion. During the same period last year, the company posted $2.42 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.